Aligos Therapeutics (ALGS) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NextCure (NXTC) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 1.0% versus a loss of 46.5%. Over five years, NXTC leads with a -93.5% price change compared with -98.7% for ALGS. Aligos Therapeutics is the larger company by market cap ($32.9 million vs $30.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | NXTC |
|---|---|---|
| Share price | $5.28 | $6.62 |
| Market cap | $32.94M | $30.30M |
| 1-day change | -0.66% | -2.35% |
| YTD return | -43.03% | -52.22% |
| 1-year return | -46.53% | -1.02% |
| 5-year return | -98.66% | -93.53% |
| EPS (TTM) | $-7.41 | $-8.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $15.74 |
| 52-week low | $3.98 | $1.55 |
| Distance from 52-week high | -61.47% | -57.94% |
| Analyst consensus | none | none |
| Avg. price target upside | +892.99% | +202.11% |
| Average volume | 88.98K | 2.11M |
| Shares outstanding | 5.44M | 4.58M |
| Employees | 82 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed ALGS by 45.5 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
ALGS vs NXTC FAQ
Which is bigger, Aligos Therapeutics or NextCure?
Aligos Therapeutics (ALGS) is larger, with a market capitalization of $32.94M compared with $30.30M for NextCure (NXTC).
Which stock has performed better over the past year, ALGS or NXTC?
NXTC returned -1.02% over the past 12 months, compared with -46.53% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and NextCure in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Aligos Therapeutics and Biotechnology: Pharmaceutical Preparations for NextCure.